Treatment of EB virus positive diffuse large B cell lymphoma / 国际肿瘤学杂志
Journal of International Oncology
; (12): 385-388, 2021.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-907551
Biblioteca responsável:
WPRO
ABSTRACT
Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma (DLBCL) is a rare type of B cell lymphoma associated with chronic EBV infection. The main subtype is activated B cell-like and it′s invasive. The response to combined chemotherapy is worse than that of EBV negative patients, and the prognosis is poor. As the researches on pathogenesis and biological characteristics of EBV positive DLBCL deepen, new therapeutic strategies are emerging, such as antiviral therapy, monoclonal antibody, inhibitors of signaling pathway and immunotherapy including cellular immunotherapy and immune checkpoint inhibitor. These new therapeutic strategies can improve the efficacy and reduce the occurrence of adverse reactions.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2021
Tipo de documento:
Artigo